Switzerland’s Roche is buying UK-based Tusk Therapeutics in a deal that could hit EUR 655 million.

Shares of Molecular Templates were up more than 52 percent after announcing a deal with Takeda that could be worth up to $632 million to develop CD38-targeted engineered toxin bodies.